#1MediPharm Labs Extraction Ahead of the Curve A Trusted Global Leader in High-quality, Industrial-scale Cannabinoid-based Derivatives TSX-V: LABS OTCQB: MEDIF FSE: MLZ Management Presentation April 2019 medipharmlabs.com#2abv EXTRAC F Disclaimer April 2019 - This presentation was prepared by management of MediPharm Labs Corp. ("MediPharm Labs"). The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in MediPharm Labs, and (c) is not to be considered as a recommendation by MediPharm Labs that any person make an investment. Any investment in the securities of MediPharm Labs is speculative and involves a number of risks that should be considered by any prospective investor. Additional information regarding MediPharm Labs, including the risks and uncertainties outlined in its most recent annual information form dated April 3, 2019 (the "Annual Information Form"), is available at www.medipharmlabs.com or through the SEDAR website at www.sedar.com. This presentation does not constitute an offer or solicitation in any jurisdiction to any person or entity and was not prepared in connection with any such offer or solicitation. Readers of this presentation should not construe the contents of this presentation as legal, investment, tax or other advice. CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION MediPharm Labs cautions that statements in this presentation (including any oral commentary that may accompany it) are forward-looking statements. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our future results of operations or financial condition, prospects, business rategy and plans and objectives of management for future operations, the success of our sales and marketing efforts, the extent of market acceptance for our products and services, our ability to develop and bring to market new or enhanced products, our ability to develop our production facility, our international ventures, the cannabis and cannabis industry and regulatory environment and continuing uncertainty in the global economic environment, are forward-looking statements. The words "believe," "will," "may," "estimate," "continue," "projection", "anticipate," "intend," "should," "plan," "expect," "predict," "could," "potentially" or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results and trends in the future may differ materially from those suggested or implied by the forward-looking statements depending on a variety of factors. The forward-looking statements contained in this presentation speak only as of the date the statements are made and are based on information available to the MediPharm Labs at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Such statements are based upon the current beliefs and expectations of Medi Pharm Labs' management and are subject to significant business, social, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors. Many assumptions are based on factors and events that are not within the control of MediPharm Labs. Actual future results may differ materially from historical results or current expectations. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking information contained in this presentation, those results or developments may not be indicative of results or developments in subsequent periods. Although MediPharm Labs has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Forward-looking information contained in this presentation is based on MediPharm Labs' current estimates, expectations and projections, which MediPharm Labs believes are reasonable as of the current date. MediPharm Labs can give no assurance that these estimates, expectations and projections will prove to have been correct. You should not place undue reliance on forward-looking information, which is based on the information available as of the date of this presentation. Forward-looking information contained in this presentation is as of the date of this presentation and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this presentation is intended to be nor may be construed as a profit forecast. Additional information related to MediPharm Labs, including risks and uncertainties and the Annual Information Form, can be found on its SEDAR profile at www.sedar.com. MediPharm Labs | 2#3MediPharm Labs A front-runner in cannabis extraction and purification. State-of-the-art technology, cutting edge proprietary methodologies. A trusted partner, delivering pure, safe and precisely dosable cannabis concentrates for private label advanced derivative products. MediPharm Labs | 3#4MediPharm Labs - A Differentiated Cannabis Growth Opportunity Leader Extraction Only Canada's cannabis oil extraction leader High Growth + Margin >>> Singular & Strategic focus on high growth & high margin segment 1st Mover Advantage Technology Expertise Licensing Scale Scale Highly scaled operations 250,000 kg expected Q2 2019 Revenue $ $10 million revenue - first month sales December 2018 Predictable Cash Flow 5 private label sale agreements 5 multi-year processing agreements, more to come M&A and International Growth Opportunities Australia and Asia Pacific targets European export Global M&A and JV opportunities MediPharm Labs | 4#5Capital Structure and Ownership Stock Performance TSX-V:LABS - Initiated Trading October 4, 2018 2018-10-09 IL that tel 2018-11-07 talk shut out the the had the اس سلسل سارا 2018-12-06 2019-01-04 Volume 2019-02-02 -Price 2019-03-03 200% 180% 160% 140% 120% 100% 80% 60% 40% 20% 0% 2019-04-01 Ownership Management and Insiders MMJ Phytotech Horizons ETF Other 57% 40% 1% 2% Capital Structure Common Shares o/s Options Warrants Fully diluted Total potential influx from Options & Warrants Cash Position Debt (Mortgage) Share Performance Market Close April 1, 2019 106.3 million Balance Sheet (at December 31, 2018) Market Capitalization 10.5 million 21.8 million 139.7 million ~$19 million $7.85 million $6.0 million $5.66 $601 million MediPharm Labs | 5#6Q4 2018 Financial Summary Revenue (¹) Gross Profit Gross Margin % Net loss Q4 2018 $'000s 10,198 3,967 39% (3,542) (3,366) Q4 2017 $'000s 2,129 (742) (695) (695) 2018 $'000s 10,198 3,967 39% (8,466) Operating loss - as reported Adjusted EBITDA (²) Adjusted EBITDA(²) margin % 21% (1) Revenue of $10.2 million, commencing November 9 after receipt of sales licence from Health Canada (2) Adjusted EBITDA includes $0.74M Share-based compensation, $4.23M Transaction fee and $0.53M Depreciation (8,052) (875) (9%) 2017 $'000s (995) (948) (948) Adjusted EBITDA is not a recognized performance measure under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. Adjusted EBITDA is included as a supplemental disclosure because Management believes that such measurement provides a better assessment of the MediPharm Labs' operations on a continuing basis by eliminating certain non-cash charges and charges or gains that are nonrecurring. Adjusted EBITDA is defined as net loss excluding interest, taxes, depreciation and amortization, and share-based compensation and listing expense. Adjusted EBITDA has limitations as an analytical tool as it does not include depreciation and amortization expense, interest income and expense, taxes, share-based compensation and transaction fees. Because of these limitations, Adjusted EBITDA should not be considered as the sole measure of the MediPharm Labs' performance and should not be considered in isolation from, or as a substitute for, analysis of the MediPharm Labs' results as reported under IFRS. The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is operating income (loss). A reconciliation of the Company's operating loss to Adjusted EBITDA and further information is available under "Reconciliation of non-IFRS measures" in the MediPharm Labs' Management's Discussion and Analysis for the year ended December 31, 2018 for additional information. MediPharm Labs | 6#7Key Milestones - First Fully Licensed Extraction Company in Canada Oct 4, 2018 "LABS" trades on TSX-V 1 2 Supreme. TSXV:FIRE Nov 12, 2018 Sales License approved Nov 14, 2018 3 yr. tolling signed 3 4 Dec 24, 2018 Health Canada approves expansion 5 Nov 29, 2018 Up to 900 kg/18 month extract agreement CORPORATION CANOPY GROWTH 6 TERRASCEND Jan 8, 2019 Large tolling agreement signed 7 Jan 7, 2019 "MEDIF" trades on OTCQB 8 Feb 12, 2019 $35 million oil sale - $7.5 million upfront 9 Jan 16, 2019 $10 million sales in 1st month 10 Feb 12, 2019 $85 million potential revenue/15 months from signed contracts Feb 21, 2019 1st international agreement to export to AusCann in Australia 11 10 April 1, 2019 5,000 KG dried cannabis acquired for private label Last 2 weeks March 2019 MediPharm Labs | 7#8Wholesale + Private Label + Processing Multiple Agreements Completed O Wholesale + Private Label +15 Dried cannabis supply agreements Supreme. CRONOS GROUP Processing +5 Concentrate program agreements Supreme. JUC James & Wagner *OOTS VA K* UP TERRASCEND emerald™ HEALTH THERAHUTIC O o o ooooo MediPharm Labs CANOPY GROWTH CORPORATION +5 Sale agreements o Oil + Tinctures Capsules Brand g% API MediPharm Labs | 8#9Largest Canadian Extraction Footprint - Domestic & Global Distribution Canadian LP with production and sales licence BARRIE, ONTARIO ● ● CANADA ● ● ISO standard critical environments Built to exceed cGMP standards ● EU GMP Certification expected 70,000 Sq Ft with 150,000 kg capacity Expanding expected to 250,000 kg capacity by Q2/19 MediPharm Labs EUROPE ASIA PACIFIC VICTORIA, AUSTRALIA • 10,000+ Sq Ft facility Serving emerging medical cannabis segment ● ● Import/export hub into Asia Pacific and North America AUSTRALIA MediPharm Labs | 9#10MediPharm Labs Extraction Processes PRIMARY EXTRACTION SUPERCRITICAL CO₂ Receiving dry bud, trim & shake MILLING Vacuum dry and DECARBOXYLATE plant material EXTRACT with Supercritical CO₂ Crude Extract 50% Light Terpene Fraction 1 Ethanol Solvent Wax & Lipids WINTERIZE & FILTER Tinctures, Soft Gels Crude Resin 75+% ROTARY EVAPORATION Winterized Oil SECONDARY PROCESSING DISTILLATION + CHROMATOGRAPHY Heavy Terpene Fraction 2 Residue Fraction 4 SHORT PATH DISTILLATION Distillate ~ 90% Cannabinoid Fraction 3 Vapeables, Edibles, Topicals ISOLATES CENTRIFUGE CHROMATOGRAPHY Isolate 99.9% Cannabinoid Fraction 5 Active Pharmaceutical Ingredients MediPharm Labs | 10#11Market Opportunity: Retail Revenue Potential Sensitivity 150,000 kg Annual Capacity Increasing to 250,000 kg by Q2/19 Facility Capacity (Flower) Capacity Utilization Process Throughput (Flower) Flower to active cannabinoid conversion (Note A) Active Cannabinoid Content Active Cannabinoid Content Price per active component (Note B) Revenue at retail per annum (kg) (%) (kg) (%) (kg) (mg) M (mg) ($) B 150,000 50% 75,000 10% 7,500 7,500M $0.11 $0.880B 150,000 100% 150,000 10% 15,000 15,000M $0.11 $1.65B 250,000 50% 125,000 10% 12,500 12,500M $0.11 $1.37B Note A Cannabinoid recovery from flower ranges between 10% - 20%; active cannabinoid concentration in crude ranges from 70% - 80% Note B Source: Based on aggregated pricing data per mg on Harvest Medicine website: https://hmed.ca/pricewatch/ ranging between $0.10- $0.12 per mg. Potential retail revenue is not reflective of future revenue guidance or management expectations for actual financial results. Pricing reflects retail pricing to end consumer in Canadian market inclusive of excise tax of approximately 10%. MediPharm Labs | 11#12MediPharm Labs PORTERE CHTER PRIME Executing on International Growth First Move: Victoria, Australia expected operational H2 2019 pending licensing ● Gateway to Asia Pacific markets Short term: hub for import/export Long term: production facility Actively seeking import/export opportunities (where federally permissible) Construction is underway with launch expected H2 2019 1 hour south-east of Melbourne Manufacturing licence application submitted for review (Australian Office of Drug Control) Working with many cultivation partners Majority holder (80%) of subsidiary MediPharm Labs Australia Pty. Ltd. MediPharm Labs | 12#13Summary and Future Catalysts 1st Mover Advantage Leader Extraction Only EU GMP Certification expected H2 2019 High Growth + Margin « First oil shipment to AusCann in Australia Scale ll Increasing dry cannabis supply Wholesale/Private label production and distribution agreements Revenue Expansion to 250,000 kg annual capacity expected by Q2 2019 $³ Canadian legalization of edibles & vapeables Fall 2019 creates another significant addressable market Predictable Cash Flow M&A and International Growth Opportunities Completion of Australian extraction facility M&A or JV opportunities MediPharm Labs | 13#14Exceptional Management Team with Deep Experience Pat McCutcheon Chief Executive Officer 15-year career in pharmaceutical sales and marketing for a wide range of products. Recently led the Hospital Division for Renal and Mental Health products at Janssen Pharmaceuticals (J & J). Janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson SANOFI Ahmed Shehata General Counsel & Head of Corporate Development 10 years in Business Law focused on securities, mergers and acquisitions, and corporate finance. Previously counsel for numerous cannabis companies and going public transactions. Sybil Taylor Chief Marketing Officer 25-year marketing career in consumer- packaged goods. Experienced in strategic brand and product development and fully integrated communications in regulated alcohol and cannabis industries. Keith Strachan President, Co-Founder A healthcare business development expert, bringing government Supply Chain Management experience from government ministries, and consultancy in Public Sector RFPS, compliance, licensing and planning. RVH Royal Victoria Regional Health Centr Kirk Binns Executive VP, Global Markets A serial entrepreneur in the North American deregulated energy markets, leading market expansions and client acquisitions across multiple markets. Jason Nalewany VP Finance A CPA-CA with cannabis experience, Jason has provided financial expertise to public entities in capital market strategies, M&A advisory, valuation, financial forecasting and due diligence. David Mayers Chief Operating Officer 28 years of pharmaceutical leadership in multi- national and small organizations. Experienced in management of Controlled Substances, R&D, Quality, Lean Sigma, Supply Chain and strategy. PURDUE Chris Hobbs Chief Financial Officer 18-year career in Finance, Chris has acted as Chief Financial Officer for several private and public companies operating in the resource, health sciences and technology sectors. Laura Lepore VP Investor Relations & Communications Award winning Investor Relations and Communications Executive experienced in corporate and financial communications, public relations and capital markets for global organizations. MediPharm Labs | 14#15Exceptional Management Team with Deep Experience Dr. Chris Talpas Vice President, Quality & Scientific Affairs A Chromatography expert with 24-years in the bio-pharmaceutical field. Deep experience in the qualification/validation of complex quality systems, processes and equipment. Anuja Siwakoti Director of Global Regulatory and Scientific Affairs Anuja is a senior leader in cannabis research, academia and regulated cannabis consulting, specializing in GPP/GMP audits, Health Canada licensing and navigating global regulations. Saravan Subramaniam Director, Project Management Office Saravan has expertise leading engineering and technical services projects in the pharmaceutical and automotive industries including product launches and complex manufacturing facility designs. Dr. Ina Dubinsky Lead Scientist - Secondary Processing Experienced in R&D, testing and extraction of cannabis/hemp, isolation and purification of cannabinoids by vacuum distillation/filtration and RF column chromatography within FDA/GMP. Warren Everitt Managing Director, MediPharm Labs Australia Warren brings senior leadership in Asia Pacific through his international digital marketing agency, and career in sales and marketing, consulting to some of the world's biggest companies. Lorna Willner Director of Human Resources Lorna has a 25-year career as a collaborative leader developing best practices in recruitment, onboarding and coaching to build high performing teams aligned to company goals and values. Michael Perron Vice President, Business Development A CPA with a MAcc, Mike has spent over 10 years in professional services focused in Management Consulting, Enterprise Risk, and Transaction Advisory Services, leading the national cannabis practice. Dr. Jake Golding Director of Quality - Australia 20-years in bio-tech, with expertise in chemistry, commercial production and operations as well as quality systems. Experience includes registration and qualification of facilities, processes and equipment. Paul Hamelin Director of Security Paul has a 35-year career in policing. He is the Executive Director of Ontario Police Technology Information Co-operative and former president of the Ontario Association of Chiefs of Police. MediPharm Labs | 15#16MediPharm Labs Please Contact for Additional Information Pat McCutcheon Chief Executive Officer Laura Lepore Vice President, Investor Relations and Communications Email: [email protected] Phone: +1 705 719 7425 ext. 216 TSX-V: LABS OTCQB: MEDIF FSE: MLZ medipharmlabs.com in /medipharm-labs P @medipharmlabs @medipharmlabs f@medipharmlabs